WO2016179472A3 - Modulation of natural killer cell tolerance - Google Patents

Modulation of natural killer cell tolerance Download PDF

Info

Publication number
WO2016179472A3
WO2016179472A3 PCT/US2016/031150 US2016031150W WO2016179472A3 WO 2016179472 A3 WO2016179472 A3 WO 2016179472A3 US 2016031150 W US2016031150 W US 2016031150W WO 2016179472 A3 WO2016179472 A3 WO 2016179472A3
Authority
WO
WIPO (PCT)
Prior art keywords
natural killer
modulation
killer cell
cell tolerance
reversing
Prior art date
Application number
PCT/US2016/031150
Other languages
French (fr)
Other versions
WO2016179472A2 (en
Inventor
Scott E. Strome
Edward SO
Original Assignee
University Of Maryland, Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Maryland, Baltimore filed Critical University Of Maryland, Baltimore
Publication of WO2016179472A2 publication Critical patent/WO2016179472A2/en
Publication of WO2016179472A3 publication Critical patent/WO2016179472A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Embodiments of the disclosure concern methods and compositions related to reducing, inhibiting, reversing or preventing immune tolerance associated with antibody therapy in a subject. In specific embodiments, the disclosure concerns reducing, inhibiting, reversing or preventing natural killer (NK) cell tolerance occurring as a result of antibody-dependent cell- mediated cytotoxicity. Certain aspects utilize inhibitors of certain cell surface molecules on NK cells, including TIM-3, CCR7, and B7-H1.
PCT/US2016/031150 2015-05-07 2016-05-06 Modulation of natural killer cell tolerance WO2016179472A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562158221P 2015-05-07 2015-05-07
US62/158,221 2015-05-07

Publications (2)

Publication Number Publication Date
WO2016179472A2 WO2016179472A2 (en) 2016-11-10
WO2016179472A3 true WO2016179472A3 (en) 2016-12-01

Family

ID=57218037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/031150 WO2016179472A2 (en) 2015-05-07 2016-05-06 Modulation of natural killer cell tolerance

Country Status (1)

Country Link
WO (1) WO2016179472A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3030765A1 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
AU2017371179B2 (en) 2016-12-09 2022-07-14 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
WO2018107082A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Methods of treating inflammatory disorders with multivalent fc compounds
JOP20190187A1 (en) 2017-02-03 2019-08-01 Novartis Ag Anti-ccr7 antibody drug conjugates

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020071842A1 (en) * 2000-06-05 2002-06-13 Gumperz Jenny E. Soluble CD1 compositions and uses thereof
US20030022292A1 (en) * 2001-06-07 2003-01-30 Gray-Owen Scott D. Ligation of CEACAM1
US20120219540A1 (en) * 2005-05-12 2012-08-30 Bristol-Myers Squibb Company Compositions and methods for modulating immune responses
WO2013173820A2 (en) * 2012-05-18 2013-11-21 Scott & White Healthcare Bispecific scfv immunofusion (bif)
WO2014093870A2 (en) * 2012-12-13 2014-06-19 The Schepens Eye Research Institute, Inc. Use of c-c chemokine receptor type 7 (ccr7) inhibitors
US20150079109A1 (en) * 2013-09-13 2015-03-19 Beigene, Ltd. Anti-PD1 Antibodies and their Use as Therapeutics and Diagnostics

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020071842A1 (en) * 2000-06-05 2002-06-13 Gumperz Jenny E. Soluble CD1 compositions and uses thereof
US20030022292A1 (en) * 2001-06-07 2003-01-30 Gray-Owen Scott D. Ligation of CEACAM1
US20120219540A1 (en) * 2005-05-12 2012-08-30 Bristol-Myers Squibb Company Compositions and methods for modulating immune responses
WO2013173820A2 (en) * 2012-05-18 2013-11-21 Scott & White Healthcare Bispecific scfv immunofusion (bif)
WO2014093870A2 (en) * 2012-12-13 2014-06-19 The Schepens Eye Research Institute, Inc. Use of c-c chemokine receptor type 7 (ccr7) inhibitors
US20150079109A1 (en) * 2013-09-13 2015-03-19 Beigene, Ltd. Anti-PD1 Antibodies and their Use as Therapeutics and Diagnostics

Also Published As

Publication number Publication date
WO2016179472A2 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
MY199019A (en) Pd-1 antibodies
PH12020550039A1 (en) Sialyltransferases and their use in producing sialylated oligosaccharides
WO2014201362A3 (en) Computer vision application processing
MX2016006684A (en) Food and beverage products comprising allulose (psicose).
WO2014158811A8 (en) Newcastle disease viruses and uses thereof
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MX2016013512A (en) Systems and methods for concurrent spectrum usage within actively used spectrum.
WO2016196912A8 (en) Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
WO2019123015A8 (en) Lysophosphatidylcholine compositions
WO2016179472A3 (en) Modulation of natural killer cell tolerance
WO2017132746A8 (en) Ubiquitin variants and uses thereof as 53bp1 inhibitors
MX2019002346A (en) Compositions comprising rebaudioside j.
AU2014225575A8 (en) Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same
MX2021006458A (en) Yeast cell wall enriched in mannan oligosaccharide protein.
EP3886877A4 (en) Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
TN2017000465A1 (en) The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
EP3793574A4 (en) Manipulating arid5b expression in immune cells to promote metabolism, survival, and function
AU2014249346A8 (en) High purity ovarian cancer stem cells for active autologous immune therapy
WO2016081773A3 (en) Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides
PH12014501223A1 (en) Compositions and methods for the stability of reactive amino acids in a food matrix
EP4233565A3 (en) Seasoning composition, snack food comprising said composition and method of seasoning a snack food
WO2016044093A3 (en) Aeration discs and methods for using same
WO2020012244A3 (en) Treating ulcerative colitis with brazikumab
ZA202103634B (en) Use of an egg grafted with tumor cells in order to study the anti-cancer effectiveness of immune therapies in the absence of immune effector cells other than those in the grafted egg
WO2016049522A3 (en) Compositions comprising ch505 envelopes, and trimers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16790142

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16790142

Country of ref document: EP

Kind code of ref document: A2